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Abstract 20 
SHANK3, a synaptic scaffold protein and actin regulator, is widely expressed outside of the 21 
central nervous system with predominantly unknown function. Solving the structure of the 22 
SHANK3 N-terminal region revealed that the SPN-domain is an unexpected Ras-association 23 
domain with high affinity for GTP-bound Ras and Rap G-proteins. The role of Rap1 in 24 
integrin activation is well established but the mechanisms to antagonize it remain largely 25 
unknown. Here, we show that SHANK1 and SHANK3 act as integrin activation inhibitors by 26 
sequestering active Rap1 and R-Ras via the SPN-domain and thus limiting their 27 
bioavailability at the plasma membrane. Consistently, SHANK3 silencing triggers increased 28 
plasma membrane Rap1 activity, cell spreading, migration and invasion. Autism-related 29 
mutations within the SHANK3 SPN-domain (R12C and L68P) disrupt G-protein interaction 30 
and fail to counteract integrin activation along the Rap1/RIAM/talin axis in cancer cells and 31 
neurons. Altogether, we establish SHANKs as critical regulators of G-protein signalling and 32 
integrin-dependent processes. 33 
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Introduction 36 
Integrins are heterodimeric transmembrane receptors that couple the extracellular matrix 37 
(ECM) to the actin cytoskeleton and undergo conformational switching from a low-affinity 38 
“inactive” to a high-affinity “active” state. In the active conformation integrins enhance cell 39 
signalling and inappropriate integrin activation is linked to several pathologies including 40 
inflammation and cancer1. Hence, understanding integrin activity regulation is of major 41 
clinical relevance. Integrins are also crucial regulators of important processes in the brain 42 
such as neuronal cell migration, axonal outgrowth and synaptic plasticity2 but the role of 43 
integrin activity regulation in these processes remains to be fully investigated.  44 
Talin recruitment to the β-integrin tail triggers integrin activation and is regulated through the 45 
activity of the Rap1 GTPase and its effector Rap1-interacting adaptor molecule (RIAM)3-5. 46 
Integrin activity can be counterbalanced by integrin inactivating proteins such as SHARPIN, 47 
ICAP-1 and filamin1,6,7, all of which interact with integrins and directly or indirectly interfere 48 
with talin-mediated integrin activation. However, potential mechanisms to block integrin 49 
activation at the level of Rap G-proteins remain unidentified. 50 
SH3 and multiple ankyrin repeat domains (SHANK) 1-3  are a family of scaffold proteins 51 
found in the postsynaptic density (PSD) of excitatory synapses and are indispensable for 52 
normal brain function8,9. In addition, SHANK proteins are expressed in peripheral organs 53 
with largely unknown functions. Genetic alterations in SHANK3 are responsible for a 54 
spectrum of neuropsychiatric disorders, including autism spectrum disorders (ASD), 55 
schizophrenia, intellectual disability and manic-like behaviour10-16 and chromosomal 56 
deletions of the region containing SHANK3 cause Phelan-McDermid syndrome (22q13 57 
deletion syndrome) which manifests as neurological symptoms and affects many peripheral 58 
organs including the dermis, congruent with the wide tissue-distribution of SHANK317,18. 59 
Recently, autism-like symptoms of Shank3-deficient mice were reversed by targeting actin 60 
regulators or Akt signalling19,20 and adult restoration of Shank3 in mice improved many of the 61 
autistic-like symptoms21. Thus, SHANK3 seems to actively contribute to signalling and the 62 
regulation of the cell cytoskeleton during and post development. 63 
 64 
  65 
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Results 66 
SHANK1 and SHANK3 inhibit integrin activation 67 
We previously performed a druggable genome-wide RNAi screen in 13 different human cell 68 
lines and analysed integrin activity using monoclonal anti-β1 integrin antibodies (9EG7 and 69 
12G10) that specifically recognize the active receptor conformation22. Re-evaluation of these 70 
data revealed increased integrin activation (detected with either one or both of the antibodies) 71 
following SHANK1 or SHANK3 silencing in nine and in five out of the 13 cell lines tested, 72 
respectively (Fig. 1a). Although both SHANK1 and SHANK3 are major PSD scaffolding 73 
proteins in excitatory synapses, they are also widely expressed outside of the nervous system 74 
with currently unknown functions (publicly available GTEx portal data; Fig. 1b).  75 
To validate a role for SHANK1 and SHANK3 in inhibiting integrin activation we 76 
employed a dual colour flow cytometric assay to measure cell-surface active integrins (based 77 
on the binding of a recombinant integrin ligand fragment, fibronectin [FN] repeats 7-10) 78 
relative to total cell-surface integrins in CHO cells23,24. Expression of rat Shank3-mRFP (Fig. 79 
1c) or rat Shank1-GFP (Supplementary Fig. 1a) significantly reduced integrin activity, 80 
compared to mRFP or GFP alone (Fig. 1c and Supplementary Fig. 1a) without altering total 81 
β1-integrin surface levels. Moreover, the magnitude of Shank-mediated integrin inhibition 82 
was comparable to the effect of overexpressing SHARPIN-GFP (Fig. 1c), a known β1-83 
integrin inhibitor in several cell types7,25,26. To confirm these findings we analysed integrin 84 
activity in the human HEK293 and MDA-MB-231 cell lines with opposing patterns of 85 
SHANK3 and SHANK1 expression (Supplementary Fig. 1b, 1c). Silencing of SHANK3 in 86 
SHANK3–expressing HEK293 cells or SHANK1 in SHANK1-expressing MDA-MB-231 cells 87 
(Supplementary Fig. 1d) triggered a significant increase in cell-surface active integrin levels 88 
(Fig. 1d,e and Supplementary Fig. 1e,f) without affecting total cell-surface receptor 89 
expression. SHANK3-silencing was nearly as efficient in activating β1-integrins as Mn2+ (Fig. 90 
1d and Supplementary Fig. 1e) which binds to the integrin ectodomain and activates β1-91 
integrin heterodimers via an outside-in mechanism27. Importantly, reintroduction of rat 92 
Shank3-mRFP or rat Shank1-GFP reversed the increased integrin activity in SHANK3- or 93 
SHANK1-silenced cells and reduced integrin activity levels in control-silenced cells (Fig. 1e 94 
and Supplementary Fig. 1f). Thus, the ability of SHANK3- and SHANK1-targeted siRNAs to 95 
increase β1-integrin activity was specifically due to the loss of each SHANK isoform rather 96 
than off-target effects.  97 
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To explore whether murine Shank3 regulates integrin activity as well, we isolated mouse 98 
mammary epithelial cells (MMECs), known to express Shank328 (Supplementary Fig. 1g), 99 
and mouse mammary fibroblasts (MMFs) lacking Shank3 (Supplementary Fig. 1g), from WT 100 
Shank3αβ+/+ and Shank3αβ-/- mutant mice (specifically lacking the long α (containing SPN, 101 
Ank and SH3 domains) and β (containing Ank and SH3 domains) isoforms of SHANK3)29,30 102 
We observed markedly higher active integrin levels in MMECs, but not MMFs, isolated from 103 
Shank3αβ-/- compared to WT mice (Shank3αβ+/+) (Fig. 1f and Supplementary Fig. 1h,i). 104 
Taken together, these data indicate that SHANK1 and SHANK3 function as inhibitors of β1-105 
integrin activation.  106 
SHANK1 and SHANK3 localize to membrane ruffles with inactive integrins 107 
Next we investigated the subcellular localization of SHANKs in cells. In the absence of 108 
suitable reagents to detect endogenous SHANKs with immunofluorescence we expressed 109 
Shank3-mRFP (Fig. 1g; Supplementary figure 1j,k) or Shank1-GFP in MDA-MB-231 cells 110 
(Supplementary Fig. 1j). Both SHANK proteins localized to the periphery of the cell in actin-111 
rich membrane ruffles positive for the membrane marker CAAX-GFP and the inactive 112 
integrin receptor (Fig. 1g and Supplementary Fig. 1j) as well as to the nucleus (the possible 113 
nuclear function of SHANKs was not investigated here further). Conversely, no co-114 
localisation was observed between SHANKs and ECM-bound active integrins 115 
(Supplementary Fig. 1k). Membrane recruitment of SHANK3 was validated further with 116 
biochemical membrane fractionation, demonstrating SHANK3 in both the cytoplasmic and 117 
plasma membrane fractions (Fig. 1h), and with live-cell imaging showing dynamic 118 
localization of Shank3-mRFP to folding membrane areas (Fig. 1i and Supplementary video 119 
1). Thus, SHANK1 and SHANK3 appear to predominantly localize to unattached membrane 120 
ruffles together with inactive integrin and actin.  121 
SHANK1 and SHANK3 inhibit cell adhesion and spreading 122 
Consistent with increased integrin activation (Fig. 1), SHANK3 silencing in HEK293 cells or 123 
SHANK1 silencing in MDA-MB-231 cells promoted cell adhesion to a fibronectin-collagen 124 
matrix over time as measured with the xCELLigence apparatus (Fig. 2a and Supplementary 125 
Fig. 2a). In addition, SHANK3-silenced HEK293 cells generated significantly more, yet 126 
smaller, adhesions (Fig. 2b-2e). Interestingly, SHANK3 silencing also appeared to affect cell 127 
spreading. Downregulation of either SHANK isoform was sufficient to trigger a significant 128 
increase in cell area on the fibronectin-collagen-coated surface at 20 and 60 min post plating 129 
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compared to control-silenced cells (Fig. 2f,g and Supplementary Fig. 2b,c). Enhanced cell 130 
spreading was even more evident in cells plated on spatially restricted micropattern lines 131 
where SHANK3 silencing resulted in significantly longer cell lengths compared to the control 132 
(Fig. 2h,i). Thus, SHANK1 and SHANK3 negatively regulate integrin-mediated adhesion and 133 
spreading in cells.  134 
SHANK-mediated integrin inhibition is SHARPIN independent 135 
We next sought to explore how SHANKs regulate integrin activity. SHARPIN binds to the 136 
ARR domain of SHANKs31,32. To determine whether SHANK-mediated integrin inactivation 137 
is SHARPIN dependent, we expressed SHARPIN- or Shank1-GFP in mouse embryonic 138 
fibroblasts (MEFs) generated from WT or SHARPIN-null (cpdm) animals7 and measured 139 
surface levels of active (FN 7-10 binding), relative to total, β1-integrin. As expected, 140 
expression of both SHARPIN-GFP and Shank1-GFP reduced β1-integrin activation in WT 141 
MEFs (Supplementary Fig. 2d). Interestingly, Shank1-GFP expression decreased β1-integrin 142 
activation in cpdm MEFs to approximately the same extent as in WT MEFs (Supplementary 143 
Fig. 2d) suggesting that SHARPIN is dispensable for SHANK-mediated integrin inactivation.  144 
Autism-linked mutations in SHANK3 impair its integrin inhibitory function 145 
The N-terminal SPN domain of SHANK1 and SHANK3 (Fig. 3a) is highly conserved32 and 146 
missense mutations in the SPN domain of SHANK3 (R12C and L68P) have been detected in 147 
patients with autism33,34, highlighting the importance of the SPN domain for the proper 148 
function of SHANK3. In line with this notion, we found that expression of SHANK mutants 149 
(Shank3R12C or Shank3L68P) harbouring the identified ASD mutations32 in SHANK3-150 
silenced cells failed to rescue the increase in integrin activation triggered by loss of SHANK3 151 
(Fig. 3b). In contrast, re-expression of SHANK3 WT in the same cells completely restored 152 
integrin activity back to control levels (Fig. 3b). Furthermore, overexpression of the SPN-153 
domain alone (SPN WT) was sufficient to significantly inhibit integrin activity in CHO cells 154 
(Fig. 3c). The L68P mutation significantly, and the RC12 mutation partially, impaired SPN-155 
domain mediated integrin inhibition (Fig. 3c). An intact SPN domain was also critical for the 156 
ability of SHANK3 to regulate cell adhesion (Fig. 3d) and cell spreading (Fig. 3e). Unlike 157 
SHANK3 WT, SHANK3L68P failed to rescue SHANK3-silencing-induced effects on these 158 
processes. Thus, an intact SPN domain is a prerequisite for SHANK-dependent inhibition of 159 
integrin activity and the L68P mutation is more disruptive to SPN-domain activity than the 160 
R12C mutation.   161 
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 Given the apparent functional importance of the ASD-associated SHANK3 mutations 162 
in integrin activity regulation, we investigated the effects of SHANK3 WT and L68P mutant 163 
in neurons. Overexpression of SHANK3 WT, but not the L68P mutant, in Shank3αβ-/- 164 
cortical neurons plated on laminin, inhibited β1-integrin activity in neuronal growth cones, 165 
structures regulated by integrins and integrin down-stream signalling35,36 (Fig. 3f,g). In 166 
addition, expression of the SPN WT, but not the SPNL68P, inhibited integrin activity in 167 
growth cones of differentiating neuroblastoma cells on laminin (Supplementary Fig. 3a,b). 168 
Thus, SHANK3 inhibits β1-integrins also in neuronal cells. 169 
Three-dimensional structure of the SHANK SPN-ARR region 170 
To gain further insight into the role of the SHANK SPN domain in regulating integrin 171 
activity we determined the structure of the SPN-ARR region (the SPN domain is likely to 172 
form a compact unit with the adjacent ARR domain through intramolecular interactions32) by 173 
crystalizing the N-terminal fragment of SHANK3 (residues 1-348) and solving the structure 174 
by molecular replacement using two repeats from the core ankyrin domain of the crystal 175 
structure of human ankyrin-R (PDB: 1N11) as a template. The resulting structure, containing 176 
only 1 chain in the asymmetric unit and comprising residues 2-347 of SHANK3, was refined 177 
to 2.2Å; no electron density was detected for residues 1 and 348. Data collection and 178 
refinement statistics are given in Supplementary Table 1.  179 
The structure of the SPN-ARR fragment demonstrated two distinct domains separated by 180 
a 19-residue linker with a well-defined conformation (Fig. 3h). The C-terminal ARR domain 181 
(residues 113-337) consists of seven canonical helix-turn-helix-β-hairpin/loop ankyrin 182 
repeats arranged in a curved solenoid structure. The loop region of each repeat forms a β-183 
hairpin extending at 90o-angle from the helices towards the centre of the solenoid, typical for 184 
ARR domains 37. The β-hairpins of the repeats form a continuous flat surface that covers one 185 
end of the solenoid structure. The SPN domain (residues 8-93) positioned on top of the ARR 186 
β-hairpin surface has a ubiquitin-like fold (Ubl) closely resembling the Ubl within the talin 187 
F0 domain38,39 (Fig. 3i and Supplementary Fig. 3c). The SPN domain makes charged and 188 
polar contacts with the outer surface of the β-hairpins of repeats 2 and 3 (Fig. 3j). The N-189 
terminal part of the linker region connecting the SPN and ARR domains runs along the ARR 190 
β-hairpin surface, making a range of polar contacts (Fig. 3j). The C-terminal region of the 191 
linker folds into a 2-turn α-helix that packs against the outer end of the ankyrin repeat 1.  192 
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NMR-studies confirmed that the SPN-ARR region of SHANKs exist as an integrated 193 
unit in solution (see Supplementary Fig. 3d for the data and a detailed description).  194 
Structure of SHANK3 SPN-ARR reveals a previously uncharacterized Ras/Rap-195 
association (RA) domain 196 
The similarity between the SHANK SPN and talin F0 structures, and the reported interaction 197 
between talin F0 and Rap139,40, prompted us to investigate whether SHANK SPN is an RA 198 
domain interacting with Ras and Rap GTPases. Sequence alignment of SHANK1 and 199 
SHANK3 SPN domains with the well-characterized RA domains of RalGDS, Raf and Byr 200 
revealed the presence of consensus Ras/Rap-recognizing positive charges (residues R12 and 201 
K22) in the β1 and β2 strands of both SHANK1 and SHANK3 isoforms and a distinctive 202 
distribution of hydrophobic residues in the same region that are typically associated with RA 203 
domains41 (Fig. 4a). Furthermore, the Ras/Rap recognition side-chains of the SPN and 204 
RalGDS RA domains are well aligned in space (Fig. 4b). The only deviation from the 205 
consensus is the substitution of a positive charge, corresponding to position 52 in RalGDS, 206 
with an alanine in SHANK1 and SHANK3. However, other exposed positive charges (R38 or 207 
R25) in the vicinity of R12 and K22 may compensate for the missing charge in the α1-helix 208 
of the SHANK proteins (Fig. 4b,c). These data strongly suggest that SHANK SPN belongs to 209 
the RA family of Ubl domains.  210 
The SHANK SPN domain is a functional RA domain as it coimmunoprecipitated with 211 
WT and constitutively active (G12V mutant) forms of H-Ras but not with the dominant 212 
negative H-Ras S17N variant (Fig. 4d). Thus, SHANK3 preferentially binds to the GTP-213 
bound, active H-Ras. Additionally we found that the SHANK3 SPN domain interacts with 214 
several Ras and Rap proteins in their constitutively active and WT forms (Fig. 4e). However, 215 
in line with the notion that RA domains are promiscuous in terms of binding to several 216 
different Ras family members, but not Rho G-proteins, SHANK3 SPN did not interact with 217 
Rac1-GTP or Cdc42-GTP (Supplementary Fig. 4a). 218 
Autism-associated mutations in SHANK3 SPN impair Ras and Rap binding 219 
Next we predicted the potential effects of ASD-related mutations by superimposing the 220 
SHANK3 SPN structure on the RalGDS RA domain in complex with Ras (PDB ID 1LFD). 221 
The model demonstrated that most of the key ion-pair and polar interactions at the interface 222 
are preserved in SHANK3. In this model the position of the SHANK3 SPN R12 side-chain is 223 
optimal for forming an ion-pair with E37 of Ras (Fig. 4f). Thus, the R12C mutation identified 224 
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in ASD is expected to significantly reduce Ras binding. The second ASD mutation in the 225 
SPN domain, L68P, affects one of the key residues of the hydrophobic core (Fig. 3a) and is 226 
expected to disrupt the SPN fold, potentially causing loss of Ras interaction. As predicted 227 
from these structural analyses, the R12C and L68P ASD mutations within the SPN domain 228 
disrupted SHANK3 SPN domain interaction with active (G12V mutant) Ras as well as Rap1 229 
variants (Fig. 4g,h), even though SPN R12C retained partial binding to Rap1b in pull-downs 230 
(Fig. 4g,h).   231 
Accordingly, isothermal titration calorimetry (ITC) measurements with purified 232 
recombinant proteins indicated a very strong interaction between SHANK3 SPN-ARR and 233 
Rap1b-GTP (Kd = 0.2 ± 0.05 µM) (Fig. 4i). In comparison the Kd for SPNR12C binding to 234 
Rap1b was 2.2 ± 0.26 µM, indicating a 10-fold reduction in affinity towards Rap1b (Fig. 4j), 235 
in line with the immunoprecipitation and modelling data. The interaction between WT SPN 236 
with H-Ras-GTP was weaker (Kd = 3.3 ± 0.14 µM) (Supplementary Fig. 4b) and further 237 
reduced in the presence of the R12C mutation, and no interaction was observed with H-Ras-238 
GDP (Supplementary Fig. 4c-e). The interaction between SHANK1 and H-Ras-GTP, 239 
although weaker (Kd = 5.9 ± 0.73 µM), was within the range of affinities determined for RA 240 
domains (Supplementary Fig. 4f)41. The enthalpy of SHANK3 SPN interaction with Rap1-241 
GTP was significantly lower than that observed with H-Ras-GTP (Supplementary Fig. 4g), 242 
suggesting stronger ion-pair interactions or formation of additional hydrogen bonds at the 243 
interface between the SHANK SPN domain and Rap1-GTP. We could not ascertain the effect 244 
of the ASD-related L68P mutation in ITC experiments as we were unable to produce soluble 245 
mutant protein. However, this insolubility may point towards a role for L68 in the folding of 246 
the SPN domain. Taken together these data indicate that the SPN domain of SHANK 247 
interacts with Ras and Rap in a manner similar to other RA domain-containing proteins and 248 
that the primary effect of ASD mutations is a loss of interaction with small G-proteins. 249 
SHANK3 interferes with integrin activation by sequestering Rap1a and R-Ras 250 
Active small GTPases Rap1 4, 42-45 and R-Ras 46-48 activate integrins via inside-out signalling. 251 
To explore whether β1-integrin inhibition by SHANK3 is Rap1- and R-Ras-dependent we 252 
performed the flow cytometric-based integrin activity assays in HEK293 cells. Expression of 253 
a constitutively active Rap1a (Rap1Q63E) or constitutively active R-Ras (R-RasG38V) 254 
enhanced integrin activity (Fig. 5a and Supplementary Fig. 5a). Co-expression of Shank3-255 
mRFP inhibited the ability of both Rap1Q63E and R-RasG38V to augment β1-integrin 256 
activity which was comparable to control levels (Fig. 5a and Supplementary Fig. 5a). The 257 
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ability of Mn2+ to induce integrin outside-in activation is dependent on active Rap1 258 
availability in cells49. Accordingly, we find that Mn2+-induced integrin activity is 259 
significantly impaired in Shank3-mRFP overexpressing CHO cells (Supplementary Fig. 5b). 260 
Active Rap1a-induced integrin activation promotes marked cell spreading and flattening50. 261 
Consistent with the ability of SHANK3 to attenuate Rap1-dependent integrin activation, co-262 
expression of SHANK3 with Rap1 fully reversed the cell spreading phenotype (Fig. 5b and 263 
5c). Notably, the Rap-binding defective Shank3L68P and Shank3R12C mutants failed to 264 
counteract Rap1Q63E- or R-RasG38V-mediated integrin activation (Fig. 5a and 265 
Supplementary Fig. 5a). In hippocampal neurons integrin ligands stimulate 51 and SHANK3 266 
overexpression suppresses 52 the formation of new filopodia. We found that overexpression 267 
of Shank3 WT-GFP, but not the L68P mutant, inhibits filopodia number in MAP2-positive 268 
rat hippocampal neurites (Fig. 5d and 5e). Furthermore, WT SPN-GFP overexpression 269 
reduced filopodia number in neurites of differentiating neuroblastoma cells in comparison to 270 
GFP (Fig. 5f, g). However, the number of neurites in addition to neurite length and branching 271 
were not significantly affected by SHANK3 WT or L68P overexpression (Supplementary 272 
Fig. 5c), in agreement with the normal brain architecture reported for most Shank3-deficient 273 
mouse models53. Importantly, pharmacological inhibition of Rap154,55 reverted integrin 274 
activity (Fig. 5h) and cell spreading (Fig. 5i,j) in SHANK3-silenced cells back to control 275 
levels, suggesting that SHANK3 regulates integrin activity and cell spreading in a Rap1-276 
dependent manner. These data suggest that SHANK3 antagonizes Rap1a- and R-Ras-induced 277 
integrin activation and signalling.  278 
Rap1-GTP targeting to the plasma membrane is essential for RIAM recruitment and 279 
talin-mediated integrin activation4. In line with the ability of SHANK3 to counteract active 280 
Rap1-dependent signalling in cells, we found significant colocalization between Shank3-281 
mRFP and Rap1Q63E-GFP especially in membrane ruffles of cells (Fig. 6a). In addition, 282 
SHANK3 silencing in cells markedly increased Rap1 levels in the plasma membrane fraction 283 
(Fig. 6b) and triggered a marked enrichment of active Rap1 (Raichu-Rap1 fluorescence 284 
resonance energy transfer (FRET) probe 56) at the cell periphery close to the plasma 285 
membrane compared to a more uniform distribution of active Rap1 in control cells (Fig. 6c-286 
e). This was due to altered Rap1 localization in cells as total Rap1-GTP levels in cells were 287 
not significantly altered upon SHANK3 silencing (Supplementary Fig. 6). Thus, SHANK 288 
expression appears to regulate the bioavailability of active Rap1 particularly on the plasma 289 
membrane. 290 
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SHANKs reduce integrin-talin complexes and regulate adhesion dynamics in cells 291 
Interestingly, using the proximity ligation assay (PLA), we observed that SHANK3 silencing 292 
also promotes talin recruitment to β1-integrin (Fig. 7a,b). Furthermore, endogenous talin co-293 
immunoprecipitated with β1-integrin more efficiently in SHANK3-silenced cells (Fig. 7c; 2.1 294 
± 0.7 fold increase, n = 3). Live-cell imaging revealed that depletion of SHANK1 significantly 295 
enhanced talin recruitment to newly forming membrane protrusions in MDA-MB-231 cells 296 
(Fig. 7d,e and Supplementary Video 2). In addition, SHANK1 silencing reduced the lifetime 297 
of paxillin-positive focal adhesions (Fig. 7f,g), corroborating our data from fixed cells 298 
displaying more small adhesions and faster cell spreading. Altogether, these data suggest that 299 
SHANK-mediated segregation of Rap1 away from the plasma membrane affects talin 300 
recruitment to integrin tails and thus impedes integrin activation. However, whether 301 
SHANKs directly affect Rap1/RIAM/talin complex formation remains to be investigated.  302 
SHANK3 attenuates cell migration and invasion  303 
Increased integrin activity is implicated in altered cell migration as well as enhanced cancer 304 
cell invasion and metastasis7,57,58. To assess the role of SHANKs in cell migration we 305 
analysed random motility of SHANK-silenced cells in 2D. Time-lapse imaging revealed that 306 
depletion of SHANK3 in HEK293 cells or SHANK1 in MDA-MB-231 cells promotes a 307 
significant increase in migration velocity and a converse decrease in directionality of 308 
migration (Fig. 8a-c, Supplementary Fig. 7a-c). The effect of SHANK1 silencing on 309 
migration was fully reversed upon re-expression of Shank1-GFP (Fig. 8d-e). Previous work 310 
has linked increased random motility in 2D to enhanced cancer cell invasion in 3D59. In line 311 
with this notion we observed that SHANK1 silencing significantly promoted cell invasion into 312 
collagen hydrogels (Fig. 8f,g). Thus, increased integrin activity in SHANK-silenced cells 313 
promotes cell spreading, random migration and 3D invasion demonstrating that SHANKs are 314 
biologically important regulators of integrin function.  315 
 316 
  317 
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Discussion 318 
Regulation of integrin activity is of central importance to human health1. The critical role of 319 
Rap1 in the final steps of integrin activation is well-established5; active Rap1 recruits RIAM 320 
and talin to the plasma membrane to facilitate integrin activation. However, mechanisms to 321 
fine-tune this activation or to antagonize it are not fully understood. Here we describe that 322 
scaffold proteins SHANK1 and SHANK3 act as negative regulators of integrin activity in 323 
several cell types and consequently interfere with cell adhesion, spreading, migration and 324 
invasion (Fig. 8h), and with filopodia formation in neurites. Furthermore, we demonstrate 325 
that ASD-linked SHANK3 mutants are functionally deficient in binding to active Ras family 326 
members Rap1 and R-Ras and in mediating integrin inhibition. 327 
The crystal structure of the SHANK3 N-terminal SPN-ARR region confirmed the 328 
intramolecular interaction between both domains detected previously32. More importantly, it  329 
allowed us to elucidate the molecular mechanism by which SHANKs regulate integrin 330 
activity: (1) the SPN is an RA domain most similar to the N-terminal F0 motif of talin; (2) the 331 
SHANK SPN domain binds active, GTP-bound forms of H-Ras, Rap1 and other Ras 332 
subfamily members with high affinity; (3) ASD-related mutations in residues R12 and L68 in 333 
the SHANK3 SPN domain impair binding to Ras proteins and the ability to antagonize β1-334 
integrin activity in cells. Thus, the primary mechanism of SHANK-dependent integrin 335 
antagonism most likely stems from the ability to interfere with Rap1 or R-Ras effector 336 
binding through direct competition (Fig. 8h). It is important to note that, unlike the specific 337 
integrins expressed on leukocytes or platelets, Rap1 is not absolutely essential for β1-integrin 338 
activation and a significant pool of β1-integrin remains active in adherent cells even once 339 
Rap1 is inhibited1,7. Thus, several pathways, in addition to the Rap1-RIAM-talin axis, are 340 
likely to be involved in the spatio-temporal fine-tuning of β1-integrin activity in adherent 341 
cells at any given time. 342 
ECM ligands and specific adhesion receptors such as integrins are also important in the 343 
central nervous system, in dendritic spines and synapses60. Autism-like deficits of Shank3-344 
deficient mice can be rescued by targeting the actin regulators Rac and cofilin20, by re-345 
expressing Shank3 in adult mice21 or by inhibiting Akt signalling19. Given the ability of 346 
integrins to regulate all of these proteins, our identification of a potential role for SHANK 347 
proteins in regulating integrin activity in neuronal growth cones is most likely relevant to the 348 
neurodevelopmental disorder of these mice. 349 
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Our observation that SHANKs antagonize integrin activation, by limiting active Rap1 350 
bioavailability on the plasma membrane, provides a significant advance to our understanding 351 
of integrin activity regulation. However, SHANK3-mediated control of Ras and Rap may 352 
contribute to integrin-independent pathways as well. SHANK3 is a major scaffold proteins 353 
within the PSD of dendritic spines61. Ras activation promotes spine growth, while Rap1 354 
induces spine shrinkage62. Thus, sequestration of the activated forms of G-proteins may 355 
contribute to maintaining the balance between Ras and Rap1 activities given that the R12C 356 
mutation compromises the effect of SHANK3 overexpression on spine size and synaptic 357 
transmission52,63. Furthermore, the ability of SHANK1 and SHANK3 to sequester active Ras- 358 
and Rap-family members is likely to be important in other biological contexts including Ras-359 
driven human carcinomas. 360 
  361 
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Figure Legends 530 
Figure 1 | SHANK1 and SHANK3 inhibit β1-integrin activation 531 
a, Hierarchical clustering of β1-integrin activity (9EG7 and/or 12G10 antibodies; red: 532 
increased and blue: decreased compared to control-silenced cells (Z-score)) in 13 human cell 533 
lines upon SHANK1 or SHANK3 silencing with two independent siRNAs (#1 or #2). Results 534 
taken from a high-density cell-spot microarray.  535 
b, SHANK3 gene expression (log10RPKM: Reads Per Kilobase of transcript per Million 536 
mapped reads) in human tissues analysed using the publicly available GTEx portal (Grey 537 
region: brain tissues).  538 
c-e, Flow cytometric (FACS) analysis of integrin activity in the indicated conditions. c, 539 
Quantification shows reduced active cell-surface integrin (FN 7-10 binding) relative to total 540 
cell-surface α5β1-integrin (PB1 antibody) in Shank3-mRFP- or Sharpin-GFP-expressing cells 541 
compared to mRFP/GFP cells. d, SHANK3-silencing triggers β1-integrin activation (active 542 
β1-integrin: 9EG7 antibody; total β1-integrin: P5D2) similarly to Mn2+. e, Shank3-mRFP re-543 
expression abrogates integrin activation induced by SHANK3 silencing. Data represent mean 544 
± SEM (n = 5 (c), 3 (d), 4 (e) independent experiments; 5000 (mRFP- or GFP-positive cells) 545 
or 10000 cells (SHANK3-silenced) per experiment).  546 
f, FACS analysis (active β1-integrin: 9EG7 antibody; total β1-integrin: MAB1997) in 547 
MMECs isolated from Shank3αβ-/- mice compared to Shank3αβ+/+ (mean of 2 independent 548 
experiments; cells pooled from three mice per experiment). 549 
g, Shank3-mRFP-expressing MDA-MB-231 cells plated on fibronectin-collagen demonstrate 550 
SHANK3 localization with inactive β1-integrin (MAB13) and membrane marker CAAX-551 
GFP in membrane ruffles. Shown is a representative confocal slice (middle plane). ROI: 552 
region of interest. Scale bar = 20 μm (original image) and 10 µm (ROI). 553 
h, HEK293 subcellular fractions. Cyt: cytoplasmic; PM: plasma membrane; Na+/K+ pump: 554 
PM marker; tubulin: Cyt marker; 10 % Lys: 10 % of total lysate.  555 
i, Shank3-mRFP-expressing MDA-MB-231 cells plated on fibronectin and imaged live using 556 
a spinning disk microscope (1 picture every 10 s). Scale bar = 20 μm (original image) and 5 557 
µm (ROI).  558 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 559 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 560 
represented by dots. Statistical analysis: Student’s t-test. Statistics source data can be found in 561 
20 
 
Supplementary Table 3. Unprocessed original scans of blots are shown in Supplementary Fig 562 
8. 563 
 564 
Figure 2 | Loss of SHANK1 and SHANK3 promotes cell adhesion and spreading  565 
a, Rate of cell adherence (cell index) of HEK293 cells monitored in real-time using the 566 
xCELLigence system shows enhanced cell attachment upon SHANK3 silencing on a 567 
fibronectin-collagen substrate. BSA was used as a control for background binding. Data 568 
represent mean ± SEM (n = 4 independent experiments; average of 4 wells per experiment, 569 
20000 cells/well).  570 
b, Representative confocal images of control- and SHANK3-silenced HEK293 cells adhering 571 
to a fibronectin-collagen substrate for 15 min. Cells were stained for active β1-integrin 572 
(9EG7, green), paxillin (grey) and F-actin (phalloidin, red) to mark adhesions. Shown are 573 
confocal slices from the bottom surface. Scale bar = 10 μm (original image) and 5 µm (ROI). 574 
c-e, Quantification of the active integrin (9EG7-positive) adhesions in b showing that 575 
SHANK3-silenced HEK293 cells form more (c) but smaller (d) adhesions as compared to 576 
control-silenced cells. The distribution of adhesion size is also shown (e). Adhesions were 577 
analysed using the Cell Profiler software. Data shown as Tukey box plots (n = 15 siCTRL 578 
cells and 22 siSHANK3 cells from 3 independent experiments).  579 
f,g, Representative confocal images (f) and quantification (g) showing increased HEK293 580 
cell spreading on a fibronectin-collagen substrate upon SHANK3 silencing. Cells were stained 581 
for F-actin (phalloidin). Scale bar = 10 μm. Quantification of cell area at 20 or 60 min post-582 
plating was analysed using Image J. Data displayed as Tukey box plots (n = 47 cells (20 min) 583 
or 72 cells (60 min) from 3 independent experiments). 584 
h,i,  Representative confocal images (h) and quantification (i) showing increased HEK293 585 
cell length upon SHANK3 silencing compared to control cells on fibronectin-collagen-coated 586 
micropattern lines at 20 or 60 min post-plating. Scale bar = 10 μm. Data are displayed as 587 
Tukey box plots (n = 29 cells (20 min) or 46 cells (60 min) from 3 independent experiments).  588 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 589 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 590 
represented by dots. Statistical analysis: Student’s t-test. Statistics source data can be found in 591 
Supplementary Table 3.   592 
 593 
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Figure 3 | Structural analysis of the SHANK3 SPN-ARR region  594 
a, Illustration of SHANK3 protein domains. SPN: Shank/ProSAP N-terminal domain; ARR: 595 
ankyrin repeat domain; SH3: Src homology 3 domain; PDZ: PSD-95/Discs large/ZO-1 596 
domain; PP: proline-rich region; SAM: sterile alpha motif domain. ASD-related mutations 597 
(R12C, L68P) in the SPN domain are indicated. 598 
b,c, FACS analysis of integrin activity. b, Re-expression of Shank3-mRFP L68P or R12C in 599 
SHANK3-silenced HEK293 cells has no effect on integrin activity. c, Expression of SPN WT-600 
GFP alone inhibits integrin activity in CHO cells. Data represent mean ± SEM (n = 4 (b), 5 601 
(c) independent experiments; 5000 mRFP or GFP-positive cells analysed per experiment). 602 
Bars shown as dashed line are from Fig. 1e. 603 
d,e, HEK293 cell adhesion and spreading monitored as in 2a and 2g. Re-expression of WT 604 
Shank3-mRFP, but not L68P mutant, decreases cell adhesion (d) and spreading (20 min) (e) 605 
induced by SHANK3 silencing. (d) Data represent mean ± SEM (n = 6 independent 606 
experiments; average of 4 wells per experiment, 20000 cells/well). (e) Tukey box plots are 607 
shown (n = 138, 224, 99, 101 cells from left to right) from 3 independent experiments. 608 
f,g, Representative confocal images (f) and quantification (g) of integrin activity in 609 
Shank3αβ-/- mouse cortical neurons plated on laminin. Overexpression of SHANK3 WT, but 610 
not the L68P mutant, reduces active integrin (9EG7) in growth cones relative to area. Scale 611 
bar = 5 μm. Mean grey value (active integrin intensity) analysed with Image J software (g). 612 
Data represent mean ± SEM (n = 40 (WT) or 34 (L68P) growth cones from 3 independent 613 
experiments; cells pooled from 7-8 embryos per experiment). 614 
h, Cartoon representation of the SPN-ARR crystal structure. The SPN domain is shown in 615 
cyan, linker region in orange and ARR domain in green. Side-chains of R12 and L68, 616 
mutated in ASD, are depicted as red sticks.  617 
i, Superposition of SHANK3 SPN (cyan) and talin F0 (grey) domain structures. 618 
j, Interface between SPN and ARR domains showing side-chains of the contacting residues 619 
as sticks. Polar oxygen atoms are highlighted in red and nitrogen in blue. Protein orientation 620 
was changed slightly relative to (h) to optimize side-chain representation.  621 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 622 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 623 
represented by dots. Statistical analysis: Student’s t-test. Statistics source data can be found in 624 
Supplementary Table 3.  625 
 626 
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Figure 4 | SHANK3 interaction with Ras and Rap  627 
a, Alignment of SHANK1 (rat, Q9WV48) and SHANK3 (rat, Q9JLU4) protein sequences 628 
with the Ras/Rap recognition elements of known RA domains (Ra1GDS: rat, Q03386; C-Raf: 629 
human, P04049; Byr: yeast, P28829). Consensus recognition sequence is indicated above. 630 
Key hydrophobic and charged residues are highlighted in colour. Note that the hydrophobic 631 
residues are part of the hydrophobic core that defines the conformation of the Ras/Rap 632 
binding region.  633 
b, Superposition of SHANK3 SPN (cyan) and RalGDS RA (PDB ID 1LFD) (grey) domain 634 
structures. Key positively- and negatively-charged side-chains in both proteins are shown as 635 
sticks. 636 
c, Electrostatic surface of the SPN domain highlighting the location of positive charges (blue) 637 
aligned with key charged residues mediating Ras/Rap interaction with RA domains.  638 
d, SHANK3 SPN WT-GFP, co-expressed with constitutively active (G12V), wild-type (WT), 639 
or dominant negative (S17N) HA-tagged H-Ras in HEK293 cells, was immunoprecipitated 640 
(IP) from cell lysates, and input lysates and IP samples were analysed using anti-GFP and 641 
anti-HA antibodies, as indicated.  642 
e, SHANK3 SPN WT-GFP domain co-expressed with HA-tagged WT and mutant Ras family 643 
of G-proteins, as indicated. GFP-containing proteins were IP from cell lysates, and input 644 
lysates and IP samples were analysed as in d. 645 
f, Model of the SHANK3 SPN domain in complex with Ras based on the structure of 646 
RalGDS/active H-Ras complex (PDB ID 1LFD). 647 
g, WT and mutant SHANK3 SPN constructs co-expressed with constitutively active (G12V) 648 
forms of small GTPases H-Ras, Rap1a and Rap1b. GFP-containing proteins were IP from 649 
cell lysates and analysed as in d. 650 
h, Quantification of the data in g; binding efficiency for each HA-tagged G-protein was 651 
determined as the ratio of IP to input signal. Ratios obtained with different SHANK3 (WT 652 
and mutant) SPN constructs were normalized to SPN WT in each condition (n = 5 (H-Ras) or 653 
4 (Rap1a, Rap1b) experiments; Statistical analysis: ANOVA, followed by Dunnett's multiple 654 
comparisons test prior to normalization).  655 
i,j, ITC isotherms for the interactions between active GTP-form of Rap1B and SHANK3 656 
SPN-ARR (i), SHANK3 R12C SPN-ARR (j). Solid lines indicate fitting to the single-site-657 
binding model. Active GTP form of Rap1 was produced using non-hydrolysable GTP 658 
analogue GMPPCP. Unprocessed original scans of blots are shown in Supplementary Fig 8. 659 
 660 
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Figure 5 | SHANK3 regulates integrin activation and cell spreading by a Rap1/Ras-661 
dependent mechanism 662 
a, FACS analysis shows that SHANK3 WT-mRFP, but not SHANK3 mutant, overexpression 663 
prevents Rap1Q63E-mediated β1-integrin activation in HEK293 cells. Data represent mean ± 664 
SEM relative to mRFP and GFP expressing cells (n = 4 independent experiments; 5000 665 
mRFP/GFP-positive cells analysed per experiment). 666 
b,c, Representative confocal images (b) and quantification (c) of spreading MDA-MB-231 667 
cells transfected with GFP-Rap1Q63E alone or together with SHANK3 WT-mRFP. Staining: 668 
F-actin and DAPI (cell nuclei). Middle plane confocal image is shown. Scale bar: 10 μm. 669 
Tukey box plots represent median cell area relative to untransfected cells (n = 26, 21, 27 cells 670 
from left to right from three independent experiments).  671 
d,e, Representative confocal images (d) and quantification (e) of filopodia in rat hippocampal 672 
neurons plated on laminin. Staining: F-actin and Map2 (neurite marker). Tukey box plots are 673 
shown (n = 176 (WT), 120 (L68P) from two independent experiments). Scale bar = 20 μm 674 
(original image) and 10 µm (ROI). 675 
f,g, Representative confocal images (f) and quantification (g) of filopodia in SK-N-BE-2 676 
neuroblastoma cells plated on laminin and differentiated with retinoid acid (10 µM, three 677 
days). Shank3 SPN WT-GFP overexpression reduces filopodia density in neurites. Tukey box 678 
plots are shown (n = 76 (GFP), 62 (WT), three independent experiments). Scale bar = 20 μm. 679 
h, FACS analysis of β1-integrin activity in SHANK3-silenced HEK293 cells treated with a 680 
Rap1 inhibitor (10 μM, 1 h). (f) Data are mean ± SEM (n = 5 independent experiments; 681 
10000 cells per experiment). 682 
i,j, Representative images (i) and Image J quantification (j) of cell area in SHANK3-silenced 683 
HEK293 cells ± Rap1 inhibitor (10 µM, 1 h). Cells were adhering on a fibronectin-collagen 684 
matrix (15 min). Middle plane confocal image is shown. Scale bar = 10 μm. Data are 685 
represented by Tukey box plots (n = 30, 33, 38 cells from left to right from two independent 686 
experiments.  687 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 688 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 689 
represented by dots. Statistical analysis: Student’s t-test. Statistics source data can be found in 690 
Supplementary Table 3. 691 
 692 
 693 
Figure 6 | Loss of Shank3 promotes active Rap1 localisation to the cell edge. 694 
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a, Representative images and quantification of colocalization between Shank3 and 695 
constitutively active Rap1 (n = 18 cells from 3 independent experiments). R: Pearson’s 696 
correlation coefficient. Scale bar = 20 μm (original image) and 10 µm (ROI). b, Subcellular 697 
membrane fractionation showing increased Rap1 in the membrane fraction of SHANK3-698 
silenced HEK293 cells. Representative blots are shown (numbers indicate mean ± SEM from 699 
three independent experiments). 700 
c-e, HEK293 cells transiently expressing Raichu-Rap1 FRET probe (imaged for YFP and 701 
CFP on a confocal microscope) showing higher Rap1 activity (higher FRET ratio) at the cell 702 
periphery of SHANK3-silenced cells as compared to control-silenced cells. Representative 703 
images (left panels: YFP fluorescence; right panels: FRET ratio; scale bar = 10 μm) are 704 
shown (c). FRET ratio at the cell edge and cell body quantified using ImageJ software are 705 
presented as Tukey box plots (n = 23 cells from three independent experiments) (d) and the 706 
distribution of the FRET signal (mean ± SD; four diametric a-b measurements / cell, n = 252 707 
measurement from three independent experiment) is shown (e). 708 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 709 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 710 
represented by dots. Statistical analysis: Student’s t-test. Unprocessed original scans of blots 711 
are shown in Supplementary Fig 8. 712 
 713 
Figure 7 | SHANK1 and SHANK3 sequester active Rap1 to inhibit RIAM/talin-714 
dependent integrin activation and alter adhesion dynamics 715 
a,b, Representative PLA signal (red dots) (a) and quantification of the distribution of the PLA 716 
signal relative to the total cell area (F-actin) (b) revealing more co-localization between talin 717 
and α5-integrin following SHANK3 silencing in HEK293 cells. Data are displayed as Tukey 718 
box plots and expressed relative to control-silenced cells (n = 72 cells from three independent 719 
experiments). 720 
c, β1-integrin (P5D2) immunoprecipitation showing enhanced interaction between β1-721 
integrin and talin following SHANK3 silencing in HEK293 cells (representative blot from 722 
four independent experiments is shown). 723 
d,e, MDA-MB-231 cells transiently expressing GFP-Talin1 were plated on fibronectin and 724 
imaged live using a TIRF microscope (1 picture every 1 min for more than 3 h; scale bar = 20 725 
μm (original image) and 10 µm (ROI)) (d). The percentage of cells displaying a “talin wave” 726 
25 
 
was then counted (three biological repeats; 84 siCTRL and 86 siSHANK1 movies analysed) 727 
(e). 728 
f,g, MDA-MB-231 cells transiently expressing mEmerald-Paxillin were plated on fibronectin 729 
and imaged live using a TIRF microscope (1 picture every 1 min for more than 3 h; scale bar 730 
= 20 μm) (f). Focal adhesion lifetime was analysed using the focal adhesion analysis server 731 
(see methods) (two biological repeats; over 33 movies per condition analysed; n = 97817 732 
siCTRL and 164092 siSHANK1 adhesions analysed) (g). 733 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 734 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 735 
represented by dots. Statistical analysis: Student’s t-test. Unprocessed original scans of blots 736 
are shown in Supplementary Fig 8. 737 
Figure 8 | SHANK1 and SHANK3 regulate cell migration and invasion 738 
a-e, Random cell migration of MDA-MB-231 cells plated on fibronectin-collagen matrix 739 
recorded over 24 h by time-lapse imaging showing that SHANK1-silenced cells migrate faster 740 
and more randomly than control-silenced cells (a-c). Re-expression of Shank1-GFP in 741 
SHANK1-silenced cells rescued defects observed in cells migration (d, e). Representative cell 742 
tracks over 10 h (a) and quantification of the migration speed (b, d) and directionality (c, e) 743 
over 24 h are shown. Data were analysed using the Manual Tracking plugin (ImageJ) and are 744 
displayed as Tukey box plots (n = 36 (siCtrl) and 37 (siSHANK1) from three independent 745 
experiments (b and c); n = 36, 29, 28 from left to right from three independent experiments (d 746 
and e). 747 
f,g, Inverted invasion assay showing increased MDA-MB-231 cell invasion upon SHANK1 748 
silencing. Invasion in collagen plugs supplemented with fibronectin was visualized using a 749 
confocal microscope by imaging serial optical sections at 15 µm intervals. Individual 750 
confocal images are shown in sequence with increasing penetrance from left to right (f). 751 
Invasion was quantified using ImageJ by measuring the fluorescence intensity of cells 752 
invading 45 µm or more and expressing this as a ratio of the fluorescence intensity of all cells 753 
within the plug. Data are presented as Tukey box plots (g) (n = 6 means from three 754 
independent experiments). 755 
h, Schematic representation of SHANK-Rap1–dependent integrin inactivation regulating cell 756 
adhesion, spreading, migration and invasion. 757 
26 
 
Tukey box plots represent median and 25th and 75th percentiles (interquartile range); points 758 
displayed as outliers if 1.5 times above or below the interquartile range; outliers are 759 
represented by dots. Statistical analysis: Student’s t-test. 760 
Lilja et al., Figure 1.
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SHANK proteins limit integrin activation by directly interacting with Rap1 1 
and R-Ras  2 
Lilja et al. Online Methods and references  3 
2 
 
Methods 4 
Cell culture. CHO (Chinese hamster ovary) cells were maintained in Alpha-MEM medium 5 
(Sigma-Aldrich) supplemented with 5% fetal bovine serum (FBS, Gibco) and 2 mM L-6 
glutamine (Sigma-Aldrich). HEK293 (human embryonic kidney, ATCC) cells were grown in 7 
DMEM (Dulbecco’s modified Eagle’s medium, Sigma-Aldrich) supplemented with 10% FBS 8 
and 2 mM L-glutamine. MDA-MB-231 (triple-negative human breast adenocarcinoma, 9 
ATCC) cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 10 
and 1% non-essential amino acids (Sigma-Aldrich). Immortalized mouse embryonic 11 
fibroblasts (MEFs) isolated from wild-type and SHARPIN-null (cpdm) mice have been 12 
described previously 7. MEFs were cultured in DMEM supplemented with 10% FBS, 2 mM 13 
L-glutamate, 1 mM sodium pyruvate (Sigma-Aldrich), 1% non-essential amino acids and 14 
1:100000 β-mercaptoethanol (Sigma-Aldrich). SK-N-BE-2 neuroblastoma cells (ATCC) 15 
were maintained in DMEM:HAM’s F-12 medium supplemented with 10% FBS, 2 mM 16 
glutamine and 1% non-essential amino acids. All cells were routinely tested for mycoplasma 17 
contamination. No cell lines used in this study were found in the database of commonly 18 
misindentified cell lines that is maintained by ICLAC and NCBI Biosample. The cell lines 19 
were not authenticated. 20 
Mice and rats. Shank3αβ-deficient mice (Shank3αβ−/−) were generated by Genoway (Lyon, 21 
France) and raised on a C57BL/6 background, as described previously 29. Mice were kept in 22 
conventional open cages in pathogen-free barriers under normal food and lighting conditions. 23 
WT and Shank3αβ−/− animals were obtained from heterozygous mating. Shank3αβ−/−embryos 24 
for neuronal culture were obtained from mating of Shank3αβ- deficient parents. Animals 25 
were genotyped by PCR as described 29. In experiments using rat neuronal cultures, cells 26 
were isolated from Wistar rat (Charles River) embryos. For each experiment, one pregnant rat 27 
(4-5 months old) was sacrificed and neurons were prepared from all embryos present, 28 
regardless of gender (14-16 embryos). All mouse and rat procedures were performed in 29 
compliance with the guidelines for the welfare of experimental animals issued by the Federal 30 
Government of Germany and the Finnish Government, and covered by animal license 31 
Org766 (Hamburg, Germany) and 20006 (Turku, Finland). All rat experiments were 32 
approved by, and conducted in accordance with, the guidelines of the Animal Welfare 33 
Committee of the University Medical Center (Hamburg, Germany). 34 
Isolation of mouse mammary gland cells. Primary mouse mammary stromal fibroblasts 35 
(MMFs) and mouse mammary epithelial cells (MMEC) were isolated from the mammary 36 
3 
 
glands of adult (17-25 weeks old) virgin female mice. Briefly, the 2nd, 3rd, 4th and 5th 37 
mammary glands from three wild-type and Shank3αβ−/− mice per experiment were removed 38 
aseptically without lymph nodes, minced with surgical blades, incubated in a shaker for 2 to 3 39 
h at 37 °C in 25 - 30 ml of digestion media (DMEM /F12, 5% FBS, 5 μg/ml insulin, 50 μg/ml 40 
gentamicin) containing 2 mg/ml collagenase type XI (Sigma). The cell suspensions were 41 
centrifuged 10 min at 400 g to eliminate floating fat cells. Cell pellets were resuspended in 42 
isolation media (DMEM/F12, 50 μg/ml gentamicin, pen/strep) with 20 U/ml DNase I (Roche) 43 
and incubated for 3 min at room temperature with occasional shaking. Cells were pelleted 44 
and disaggregated by pipetting up and down 10 times in 10 ml of isolation media. After each 45 
round of pulse centrifugation at 400 g, the supernatant containing single cells was collected 46 
and pooled. After four rounds of pulse centrifugation, the pellet containing mammary 47 
epithelial ducts was collected. MMECs were trypsinised and pushed through a cell strainer 48 
(70 μm, 352350 BD Biosciences) to obtain single cells. The supernatants containing MMFs 49 
were also pelleted, and resuspended in fibroblast growth media (DMEM/F12, 5% FBS, L-50 
glutamine, pen/strep). MMEC and MMF cell suspensions were fixed with 4% 51 
paraformaldehyde (PFA) for 10 min at room temperature and resuspended in PBS.  52 
Primary neuron culture and transfection. For preparation of primary hippocampal and 53 
cortical neurons from E20 rat embryos or E16 Shank3αβ−/− mice, embryonic brain tissue was 54 
dissected, and neurons were recovered by enzymatic digestion with trypsin and mechanical 55 
dissociation. Cells were maintained in Neurobasal medium supplemented with 2% B27 56 
supplement, 0.5 mM L-glutamine, 0.1 mg/mL primocin and 25 µM glutamate (all from 57 
Invitrogen). Cells were transfected with pHAGE-EGFP-Shank3 WT or L68P construct using 58 
Amaxa Rat neuron nucleofector kit (Lonza).  59 
Transient transfections. Lipofectamine 3000 and P3000TM Enhancer Reagent (Thermo 60 
Fisher Scientific Inc) were used for transient plasmid transfections according to 61 
manufacturer’s protocol and the cells were cultured for 24 h. SiRNA silencing was performed 62 
using 100 nM siRNA and Lipofectamine® RNAiMAX Reagent (Thermo Fisher Scientific 63 
Inc) according to manufacturer’s protocol and cells were cultured for 3 days. The siRNAs 64 
targeting human SHANK1 and SHANK3 were SMARTpool ON-TARGETplus purchased 65 
from Dharmacon (SHANK1 Cat. No. L-031945-02-0005; SHANK3 Cat. No. L-024645-00-66 
0005). SiRNAs used as controls were Allstars negative control siRNA (Qiagen, Cat. No. 67 
1027281) and ON-TARGETplus Non-targeting Pool (Dharmacon, Cat. No. D-001810-10-68 
05). Rescue experiments consisted of plasmid transfections 72 h after siRNA silencing of the 69 
protein of interest. 70 
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cDNA constructs. Rat Shank3-mRFP WT, Shank3R12C-mRFP, Shank3L68P-mRFP and rat 71 
Shank1-GFP were used in this study. WT and mutant (L68P, R12C) rat Shank3/ProSAP2 72 
cDNAs have been described earlier 32. There are two alternative translation start codons in 73 
this cDNA (acc. NM_021675); we refer here to the second start codon as codon 1, so that the 74 
codon for Arg12 in the rat Shank3 cDNA corresponds to the (mutated) codon for Arg12 in 75 
the human SHANK3 gene. cDNAs were subcloned into pmRFP-N3 in frame with the mRFP 76 
coding sequence for expression of C-terminal mRFP-tagged Shank3 variants. In addition, 77 
pHAGE-EGFP-Shank3 (rat) was kindly supplied by Alex Shcheglovitov (Stanford, CA). The 78 
L68P mutation was introduced using the QuikChange II mutagenesis kit (Agilent).  79 
For expression of GFP-tagged SPN domain, the sequence coding for the rat Shank3 SPN 80 
domain was cloned into pEGFP-C1 (Clontech). For the expression of His6-SUMO-tagged 81 
fusion proteins of N-terminal portions of Shank proteins, appropriate cDNA fragments were 82 
amplified by PCR using wt or mutant Shank cDNAs as a template, and cloned into pET-83 
SUMO vectors (Champion™ pET SUMO Protein Expression System, Invitrogen). Protein 84 
expressed from pET-SUMO-Shank31-348 was used for crystallization and binding assays. For 85 
introduction of a cleavage site for the tobacco etch virus (TEV) protease, cDNA coding for 86 
amino acids SSENLYFQGSS was introduced into this vector between codons for Asn100 87 
and Leu101 by a recombinant PCR approach. Human H-Ras was cloned into pOPINJ vector 88 
(OPPF-UK) encoding an N-terminal hexa-histidine GST tag followed by 3C protease 89 
cleavage site. Rap1 isoform Rap1b (residues 1-166) was cloned into pTAC vector. For 90 
cDNAs coding for human Rac1 or cdc42 were amplified by PCR and cloned into a modified 91 
pcDNA3 vector (Invitrogen) which codes for an N-terminal T7 epitope. Constitutively active 92 
mutants were generated by PCR (initially described in 64). Human SHARPIN-GFP has been 93 
described in 7. Human constitutively active R-Ras expression clone (pEGFP-R-RasG38V) 48, 94 
human constitutively active Rap1A expression clone (CA-Rap1; pEGFP-C3-Rap1Q63E), a 95 
gift from B. Baum and S. Royale described in 65, the Raichu-Rap1 FRET probe, a gift from 96 
Matsuda M. 56, mEmerald-Paxillin-22, a gift from Michael Davidson (Addgene plasmid # 97 
54219), GFP-Talin1, mRFP and peGFP-C1 were used in this study.  98 
Antibodies, compounds and reagents. Antibodies used in the study are described in 99 
Supplementary Table 2. Phalloidin–Atto 647N (65906, Sigma-Aldrich, 1:400) and Alexa 100 
Fluor® 488 Phalloidin (A12379, Life Technologies, 1:100) were used to stain filamentous 101 
actin. AlexaFluor-conjugated secondary antibodies (488, 555, 633, 647-conjugated anti-102 
mouse, rabbit, goat, chicken and rat antibodies, Life Technologies) were used in 103 
immunofluorescence (1:300 or 1:1000 (anti-chicken)) and FACS (1:200). The 4′6-diamidino-104 
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2-phenylindole (DAPI, Life Technologies 1:10000) or DAPI-containing mounting medium 105 
(ProLong Diamond Antifade Mountant with DAPI, Thermo Fisher) were used for nuclear 106 
staining. The bovine plasma fibronectin (341631) was obtained from Merck. The collagen 107 
from calf skin (C8919), poly-L-Ornithine solution (P4957) and laminin were obtained from 108 
Sigma-Aldrich. The laminin-521 was obtained from BioLamina. Rap1 inhibitor, G5169-109 
GGTI 298 trifluoroacetate salt hydrate (Sigma-Aldrich), was dissolved in sterile DMSO. 110 
High-density cell spot microarray (CSMA) screening and Clustergram. The CSMA 111 
screening is described in 22. Here, the results of integrin activation using SHANK1 and 112 
SHANK3 siRNAs are shown. Z-scores were hierarchically clustered on the basis of 113 
uncentred Pearson correlation using Cluster 3.0 (C Clustering Library, version 1.50) 66 and 114 
visualized using Java TreeView (version 1.1.6r2) 67. RWPE1: immortalized prostate cell line; 115 
PrEC, PrSC: primary prostate cells; ALVA31, PC3, MDA-PCA2b, 22-RV1 and VCaP1: 116 
prostatic cancer cell lines; A549 and NCI-H460: lung carcinoma cells; MDA-MB-231: breast 117 
carcinoma cell line; HTC116 and SW480: colon carcinoma cell lines. 118 
GTEx portal analysis. SHANK3 gene expression in human tissues was analysed using the 119 
publicly available genotype-tissue expression (GTEx) portal 120 
(http://www.gtexportal.org/home/gene/SHANK3). 121 
Quantitative real-time polymerase chain reaction (qPCR). Total cellular RNA was 122 
extracted using the NucleoSpin® RNA kit (Macherey-Nagel) and 1 µg of the extracted RNA 123 
was used as a template for cDNA synthesis by high-capacity cDNA reverse transcription kit 124 
(Applied Biosystems) according to the manufacturer’s protocol. Expression levels of 125 
SHANK 1 and 3 were determined by TaqMan® qPCR reaction using Real-Time PCR 126 
HT7900 (Applied Biosystems). Level of glyceraldehyde 3-phosphate dehydrogenase 127 
(GAPDH) expression was used as a reference (endogenous control). Taqman® Universal 128 
Master Mix II included necessary components for qRT-PCR reaction. The following primers 129 
from Sigma were used for human samples: SHANK1 (forward 130 
CTCCCTGCGTTCCAAATGTA, reverse GGCTGCTGCTCGTACTCC, Universal 131 
ProbeLibrary probe#25); SHANK3 (forward TTCCACGGACCAAGTCTGTA, reverse 132 
GTCTTGCATCGAGGTGCTC, probe #11); human GAPDH (forward 133 
GCTCTCTGCTCCTCCTGTTC, reverse ACGACCAAATCCGTTGACTC, probe #60). 134 
Relative expression was calculated by the 2ΔΔCT method using the expression level of 135 
GAPDH as a reference for the quantification. 136 
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Western blot assay. Protein extracts were separated on SDS-PAGE under denaturing 137 
conditions (4-20% Mini-PROTEAN®TGX Gels, Bio-Rad) and transferred to nitrocellulose 138 
membrane. Membranes were blocked with 5%-milk-TBST and incubated with the indicated 139 
primary antibodies overnight at 4C followed by fluorophore-conjugated or Amersham ECL 140 
HRP-linked secondary antibodies at room temperature for 1 h. Membranes were scanned 141 
using an Odyssey infrared imaging system (Odyssey; LI-COR Biosciences) or Amersham 142 
ECL Plus™ Western blotting reagent was used and film was developed. Band intensity was 143 
determined using ImageJ software. 144 
Flow cytometry assays for β1-integrin activity. The flow cytometry assay analysing 145 
labelled fibronectin (fibronectin) repeat 7-10 binding as a measure of active cell-surface β1-146 
integrin levels, was performed as described earlier 23, 24. Cells were detached with Hyclone® 147 
HyqTase (cat: SV300.30.01, Thermo Fisher Scientific Inc) and washed once with full 148 
medium containing 10% FBS. The cells were suspended in 100 μl of 37oC serum-free 149 
medium with (1) 1:50 Alexa Fluor 647 -labelled fibronectin fragment 7-10 (fibronectin7-10), 150 
(2) 1:50 fibronectin7-10 supplemented with 5 mM EDTA (the negative control) or (3) total 151 
β1-integrin antibody (PB1 for hamster cells, P5D2 for human cells, MAB1997 for mouse 152 
cells) and 1:200 Alexa-647 conjugated secondary antibody. Cells were incubated with 153 
rotation for 40 min at room temperature. After washing once with cold tyrodes buffer (10 154 
mM Hepes-NaOH pH 7.5, 137 mM NaCl, 2.68 mM KCl, 0.42 mM NaH2PO4, 1.7 mM 155 
MgCl2, 11.9 mM NaHCO3, 5 mM glucose, 0.1% BSA), the cells were fixed with 4% PFA in 156 
PBS for 10 min at room temperature.  157 
For antibody-based analysis of active β1-integrin cell-surface levels, the flow cytometry 158 
assay was performed as described earlier 68. Briefly, PFA-fixed cells were washed with cold 159 
Tyrodes buffer and stained with active β1-integrin specific antibody (1:100 9EG7 for 160 
human/mouse cells) or total β1-integrin antibody (P5D2 for human and Mab1997 for mouse 161 
cells) for 1 h at 4oC. Cells were washed with Tyrodes buffer and followed by incubation with 162 
fluorescently conjugated secondary antibody for 1 h at 4oC. The negative control cells were 163 
stained only with secondary antibody. All antibodies were diluted into Tyrodes buffer. The 164 
fluorescence was measured by flow cytometry (FACScalibur or LSRFortessa, BD 165 
Biosciences, Franklin Lakes, NJ). The median fluorescence intensity was measured from 166 
5000 – 20000 events. Viable, single cells were gated by forward scatter (FSC) and side 167 
scatter (SSC) dot blot (Flowing Software 2.5.1). In experiments using mRFP and/or GFP 168 
constructs the mRFP and/or GFP expressing cells were gated (5000 positive cells per sample) 169 
and analysed for APC (Alexa 647) intensity. 170 
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Membrane fractionation. Adherent cells (one 10 cm dish per condition) were washed with 171 
PBS and scraped in 500 μL of hypotonic lysis buffer (10 mM HEPES-KOH pH 7.2, 0.25 M 172 
sucrose, 1 mM EDTA, 1 mM MgOAc and protease and phosphatase inhibitors (Complete 173 
and PhosSTOP tablets from Roche)). Cells were fragmented about 20 times with a French 174 
press and 40 μL of total lysate was saved. The remaining lysate was centrifuged at 1000 g for 175 
10 min to remove nucleus and cell debris. The supernatant was then centrifuged at 10000 g to 176 
collect total membrane fraction (pellet) and cytosolic fraction (supernatant). Membrane 177 
fraction was washed at least once with lysis buffer and cytoplasmic fraction was centrifuged 178 
twice. All fractionation steps were performed at 4°C or on ice. All fractions were dissolved in 179 
sample buffer for immunoblotting and analysed by SDS–PAGE followed by western blotting 180 
with the indicated antibodies. 181 
Adhesion assay using xCELLigence Real-Time Cell Analysis (RTCA). The real-time 182 
xCELLigence cell analyser RTCA (Roche Diagnostics, Germany) was used to measure cell 183 
adhesion over time. RTCA measures the impedance that is expressed as a cell index. Cell 184 
index value presents the impedance between electrodes (bottom sensors). The 96-well E-plate 185 
(Roche) was coated with fibronectin and collagen or 0.1% BSA (Gibco) in PBS, followed by 186 
blocking with 0.1% BSA in PBS, both at 37°C for 1 h. BSA-coated wells were used as 187 
negative controls. siRNA-treated and/or transfected cells (HEK293 or MDA-MB-231) were 188 
detached with Hyclone® HyqTase, washed with full medium including 10% FBS and 20000 189 
cells/well were seeded on E-plates in serum-free medium. Cell index was measured in real-190 
time. 191 
Cell spreading and immunostaining. siRNA-treated and/or transfected cells (HEK293, 192 
MDA-MB-231) were maintained in full medium and were allowed to spread for 20 min or 1 193 
h on glass-bottom dishes (MatTek corporation) previously coated with fibronectin and 194 
collagen overnight at 4°C. Transfected SK-N-BE-2 cells were plated on laminin-521-coated 195 
glass-bottom dishes and differentiated using 10 µM retinoid acid in full medium for 3 days. 196 
To study the role of Rap1 in SHANK3-silenced cells, cells were pre-treated with 10 μM Rap1 197 
inhibitor (or DMSO) and plated for 1 h on fibronectin-collagen in the presence of the 198 
inhibitor (or DMSO). Cells were fixed with 4% PFA, washed, permeabilised with 0.5% 199 
Triton-X-100 for 10 min and blocked with 1 M Glycine for 30 min at room temperature. 200 
Cells were washed and then stained with the indicated primary antibodies diluted in PBS 201 
(1:100) for 30 min at room temperature. Cells were then washed and incubated with Alexa-202 
conjugated secondary antibodies (1:300), Phalloidin–Atto 647N (1:400) or Alexa Fluor 488 203 
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Phalloidin (1:100), and 4′6-diamidino-2-phenylindole (DAPI, nuclei staining, 1:10000) in 204 
PBS for 30 min at room temperature.  205 
Transfected neurons were plated at a density of 4000/mm² (hippocampal) or 20000/mm² 206 
(cortical) in on 18-mm glass coverslips previously coated with 0.01 % poly-L-Ornithine 207 
solution (Sigma-Aldrich) for 1 hr at room temperature, followed by 4 µg/ml laminin (Sigma-208 
Aldrich) in PBS overnight. Cultures were maintained at 37 °C, 5% CO2 in a humidified 209 
incubator. Neurons were fixed at DIV1 with 4% paraformaldehyde / 4% sucrose in PBS for 210 
15 min and permeabilised with 0.1% Triton X-100 in PBS for 3 min at room temperature. Rat 211 
neurons were blocked with 10% horse serum in PBS for 1 h at room temperature, then 212 
incubated with Map2 (Antibodies online; Aachen, Germany; 1:1000 in 2% horse serum) 213 
overnight at 4°C, followed by 1 h of incubation at room temperature with Alexa-conjugated 214 
secondary antibody (1:1000 in PBS) and with 547-Phalloidine (1:40 in PBS) for 20 min at 215 
room temperature. Nuclei were stained with DAPI-containing mounting medium (ProLong 216 
Diamond Antifade Mountant with DAPI, Thermo Fisher). Mouse neurons were blocked with 217 
1 M glycine for 30 min at room temperature, washed and stained using indicated primary 218 
antibodies diluted in PBS (1:100) for 25 min at RT. Cells were then washed and incubated 219 
with Alexa-conjugated secondary antibodies (1:300).  220 
Finally, cells were washed and imaged with a confocal microscope. Cell area was analysed 221 
using ImageJ and the number and size of active integrin (9EG7) positive cell adhesions were 222 
analysed using the Cell Profiler software. Colocalisation analyses were performed using NIH 223 
ImageJ Plugin JACop. 224 
Micropatterns. Micropatterns were produced on glass coverslips as previously described 69, 225 
70. Cells were seeded on collagen-fibronectin-coated micropattern lines (width 9 μm) for 226 
either 20 min or 60 min (cells on line) before fixing with 4% PFA. Samples were stained as 227 
described above. 228 
FRET analysis of active Rap1 localization. siRNA-treated HEK293 cells transiently 229 
expressing Raichu-Rap1 FRET probe 71, 72 were plated on fibronectin-collagen-coated glass-230 
bottom dishes for 1 h at 37oC. Cells were then fixed in 4% PFA, washed with PBS and 231 
blocked in a solution of 1 M glycine for 30 min. Cells were then imaged with a confocal 232 
microscope (LSM780, Zeiss) using an 63x (NA 1.2 W) objective. The ZEN imaging software 233 
was used to generate and export the Fc images with intensities converted from the FRET 234 
index calculated for each pixel using the Youvan method. FRET ratio at the cell edge and cell 235 
body was quantified using NIH ImageJ and Cell Profiler software. 236 
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Proximity Ligation Assay (PLA). PLA detection of α5-integrin-talin interaction was 237 
performed as previously described 68. Briefly, siRNA-treated HEK293 cells were maintained 238 
in full medium and were allowed to spread for 20 min on glass-bottom dishes (MatTek 239 
corporation) previously coated with fibronectin-collagen overnight at 4°C. The coverslips 240 
were washed with PBS, fixed with 4% PFA for 15 min, washed twice with PBS and 241 
permeabilised with 0.5% Triton-X-100 in PBS for 15 min at room temperature. Cells were 242 
stained using indicated primary antibodies diluted in PBS (1:100) for 1 h at room 243 
temperature. Proximity ligation was performed according to the manufacturer’s instructions 244 
(Duolink in situ PLA, Sigma-Aldrich). PLA signals were detected with a spinning disc 245 
confocal microscope (Marianas spinning disk imaging system, Intelligent Imaging 246 
Innovations, Inc.) using 100x objective (NA 1.4 Oil, Plan-Apochromat, M27) and analysed 247 
with NIH ImageJ.  248 
Live-cell imaging. To analyse the dynamics of focal adhesions, cells were transfected with 249 
mEmerald-Paxillin (a gift from Michael Davidson, Addgene plasmid # 54219) and plated for 250 
at least 6 h on fibronectin-collagen before being imaged live on a TIRF microscope, at 37°C, 251 
in presence of 5% CO2. Images were acquired every minute for at least 3 h, using a 63x (NA 252 
1.46 Oil, alpha Plan-Apochromat, DIC) objective and an internal Optovar (1.6x 253 
magnification). Acquired videos were pre-processed using ImageJ and in particular, the 254 
contrast was adjusted and a smooth filter was applied. Focal adhesion lifetime was then 255 
analysed by uploading the videos to the focal adhesion analysis server (FAAS; 256 
http://faas.bme.unc.edu/) 73 using the following settings: detection threshold, 2; Min 257 
Adhesion Size, 2 pixels; Min FA, Phase Length (8 min); Min FAAI Ratio, 3. 258 
To analyse the dynamics of talin-containing adhesions, cells were transfected with GFP-259 
Talin-1 and plated on fibronectin-collagen before being imaged live on a TIRF microscope, at 260 
37°C, in the presence of 5% CO2. Images were acquired every minute for at least 3 h, using a 261 
63x (NA 1.46 Oil, alpha Plan-Apochromat, DIC) objective and an internal Optovar (1.6x 262 
magnification). 263 
To visualise Shank3 dynamics, cell were transfected with Shank3-mRFP and plated on 264 
fibronectin-collagen and imaged live on a spinning disk microscope, at 37°C, in the presence 265 
of 5% CO2. Images were acquired every 10 seconds for about 10 min, using a 100x (NA 1.4 266 
Oil, Plan-Apochromat, M27) objective and Evolve 512 EMCCD camera (Photometrics, 267 
Arizona, U.S.). 268 
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Cell migration. siRNA-treated and/or transfected cells (MDA-MB-231 or HEK293) were 269 
seeded on fibronectin-collagen and allowed to spread for 4 h. Cells were maintained at 37°C 270 
and 5% CO2 and cell migration was monitored using a TIRF microscope (10x objective). 271 
Point visiting was used to allow multiple positions to be imaged within the same time course 272 
and images were acquired for 24 h (one picture every ten minutes). To assess cell migration, 273 
speed and directionality, cells were tracked using the Manual Tracking plug-in of NIH 274 
ImageJ software. Results were computed and analysed by the NIH ImageJ plug-in 275 
Chemotaxis Tool. 276 
Inverted invasion assay. Inverted invasion assay was performed as previously described 74. 277 
In brief, 200 µl of collagen I (5 μg/ml; PureCol® EZ Gel, Cat. #5074-G, Advanced 278 
BioMatrix Inc., SanDiego, CA, USA) supplemented with 25 µg/ml fibronectin was allowed 279 
to polymerize in each transwell chamber, i.e. insert (ThinCertTM, pore size 0.8 μm, Greiner 280 
bio-one) for 1 h at 37°C.  Transwells were then inverted, and 100000 MDA-MD-231 cells in 281 
full medium were seeded directly onto the underside of each transwell filter. The droplets of 282 
cell suspension were covered and incubated for 4 h at 37°C in a humidified incubator to 283 
allow cells to attach to the membranes. Transwell chambers were then washed with serum-284 
free medium to remove serum. Finally, transwells were placed in serum-free medium, and 285 
medium supplemented with 10% FCS was placed on top of the collagen plug to make a 286 
chemoattractant gradient. Transwells were incubated at 37°C for 72 h. Then, collagen plugs 287 
were fixed with 4% PFA for 2 h and stained for actin (Åtto Phalloidin 647) to visualize cells. 288 
The plugs were imaged by confocal microscopy (Zeiss LSM510 META) controlled by the 289 
Zen2009 Systems Software (Carl Zeiss). Serial optical sections were imaged at 15 μm 290 
intervals with a 20x objective lens (NA 0.50 air, Plan-neofluar). Invasion was quantified 291 
using the area calculator plugin in ImageJ to measure fluorescence intensities of cells as a 292 
ratio of cells invading 45 μm or more into the collagen plug relative to total amount of cells 293 
within the plug. 294 
Microscopy. Confocal images were acquired with a laser scanning confocal microscope 295 
LSM780 (Carl Zeiss Microscopy, Thornwood, NY) using a 63x (NA 1.2 W) objective; or 296 
with a spinning disk confocal microscope (Marianas spinning disk imaging system with a 297 
Yokogawa CSU-W1 scanning unit on an inverted Carl Zeiss Axio Observer Z1 microscope, 298 
Intelligent Imaging Innovations, Inc., Denver, USA) using a 63x (NA 1.4 Oil, Plan-299 
Apochromat, M27 with DIC III Prism) objective and an Orca Flash 4 sCMOS camera 300 
(Hamamatsu Photonics K.K., Hamamatsu City, Japan) or 100x (NA 1.4 Oil, Plan-301 
Apochromat, M27) objective and an Evolve 512 EMCCD camera (Photometrics, Arizona, 302 
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U.S.); or with LSM510 META (Carl Zeiss Microscopy, Thornwood, NY) using 20 x 303 
objective (NA 0.50 air, Plan-Neofluar); or with a Leica Sp5 confocal microscope using a 63x 304 
objective (NA 1.4). Images with a TIRF microscope (Zeiss Laser-TIRF 3 Imaging System, 305 
Carl Zeiss) were acquired using a 10x objective (NA 0.25 air) or a 63x (NA 1.46 Oil, alpha 306 
Plan-Apochromat, DIC) objective with an internal Optovar (1.6x magnification) and an 307 
EMCCD camera (Hamamatsu ImageEM C9100-13; Chip size 512x512; Hamamatsu 308 
Photonics K.K., Hamamatsu City, Japan). Quantitative analysis for images was performed 309 
using ImageJ or Cell Profiler software. 310 
Immunoprecipitation of GFP-tagged proteins. HEK293 cells were transiently transfected 311 
with GFP-tagged Shank3 SPN constructs and αT7 or HA-tagged small G-proteins. Cells were 312 
lysed using IP buffer (50 mm Tris/HCl, pH 7.5, 120 mm NaCl, 0.5% Nonidet P-40, 1 mm 313 
EDTA, plus protease inhibitors pepstatin, leupeptin, and trasylol), cleared by centrifugation, 314 
and subjected to immunoprecipitation of GFP-tagged fusion proteins using GFP-trap matrix 315 
(Chromotek, Munich, Germany). Input and precipitate samples were analysed by Western 316 
blot. Bands were quantified by chemilumiscence, using a BioRad imager and ImageLab 317 
software (BioRad). For quantification of co-precipitation efficiency, intensity of precipitate 318 
signals was divided by input signals. In a second step, the ratio obtained was normalized to 319 
that obtained with SPN WT domain. 320 
Immunoprecipitation of endogenous proteins. Cells were detached with trypsin, spin down 321 
and excess liquid was removed. A total of 200 μL of lysis buffer (40 mM Hepes-NAOH, 75 322 
mM NaCl, 2 mM EDTA, 1% NP40 and protease and phosphatase inhibitor tablets) was 323 
added (per 10 cm plate). Tubes containing the lysates were rotated for 30 min at 4oC. Lysates 324 
were then spin down at 13000 rpm (∼16000 g) for 10 min at 4oC and debris were discarded. 325 
A total of 20 μL of supernatant was frozen as lysis control. The remainder of the sample was 326 
moved to new 1.5 ml tubes and 1.5 μg of antibodies added per sample. The tubes were then 327 
incubated overnight at 4oC. Lysates were immunoprecipitated with protein G Sepharose 4 328 
Fast Flow beads (GE Healthcare) for 1 h at 4oC. Finally, immunoprecipitated complexes were 329 
washed three times with wash buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40) 330 
followed by elution in reducing Laemmli buffer and denatured for 5 min at 95oC for western 331 
blotting. 332 
Rap1 activity assay. The level of active Rap1 in control and SHANK3-silenced cells was 333 
analysed using the Active Rap1 Pull-Down and Detection Kit (Thermo Fisher). SiRNA 334 
transfected HEK293 cells were lysed and active Rap1 binding to purified GST-RalGDS Rap-335 
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binding domain (RBD) was analysed according to manufacturer’s instructions using pull-336 
downs followed by western blot detection. 337 
Sample preparation for structural and ITC binding analysis. Rat SHANK3 (residues 1-338 
348) was expressed using BL21 competent cells (Invitrogen) cultured in LB (Luria Broth) for 339 
crystallization and ITC, or M9 minimal medium for NMR analysis. Cells were grown at 37oC 340 
in LB media supplemented with antibiotics to an OD600, cells were cooled to 18oC and 341 
induced using 300 μM IPTG (Isopropyl β-D-1-thiogalactopyranoside) for 16 h. Cells were 342 
pelleted by centrifugation and resuspended in 20 mM Na2HPO4 pH 7.4, 500 mM NaCl and 343 
25 mM imidazole, cells were then treated with protease cocktail inhibitor VII (Calbiochem) 344 
and bovine deoxyribonuclease (1 mg/ml) before being lysed using a French Press. Proteins 345 
were purified using nickel-affinity chromatography with a linear gradient of lysis buffer 346 
containing 500 mM imidazole. SUMO tag was cleaved with recombinant His-tagged sumo 347 
protease and removed by a reverse pass on the Ni-NTA column. Following this step the 348 
SHANK3 was shown to have > 95% purity by SDS-PAGE chromatography. SHANK3 was 349 
then exchanged into 20 mM Tris pH 7.4, 150 mM NaCl, 2 mM DTT (dithiothreitol) and 350 
concentrated to 6 mg/ml for crystallization experiments. H-Ras was expressed using Rosetta 351 
pLacI (Invitrogen) cells and purified using nickel affinity chromatography as described for 352 
SHANK3. The GST tag was cleaved with recombinant his-tagged 3C protease and removed 353 
by a reverse pass on the Ni-NTA column. H-Ras required subsequent purification using anion 354 
exchange purification using a QFF column (GE healthcare) and was shown to be > 95% pure 355 
by SDS-PAGE chromatography. Rap1b was expressed in E. coli strain CK600K. Cultures 356 
were grown at 37oC to OD595 of 0.8 and then induced with 200 μM IPTG at 18oC overnight. 357 
Protein was purified by ion exchange, followed by gel filtration, as described in 75. Active 358 
GTP form of Ras and Rap1b was produced by nucleotide exchange as described in 76 using 359 
non-hydrolysable GTP analogue GMPPCP. GDP form was generated by overnight 360 
incubation of GTPase in the presence of 50 fold molar excess of GTP in the presence of 361 
EDTA to remove magnesium, followed by the buffer exchange using PD10 column (GE 362 
healthcare). Completeness of the exchange was validated by NMR spectroscopy. 363 
X-ray crystallography. Sparse matrix crystal screening of SHANK3 (1-348) was performed 364 
using an innovadyne nanodrop screen maker at protein concentration of 6 mg/ml with a 200 365 
nl drop size (1:1 ratio) using sitting drop vapour diffusion. Crystals typically appeared in over 366 
20 conditions overnight, and thus optimization was not necessary. High resolution data was 367 
collected on crystals grown in 0.1 M HEPES pH 7.5, 0.4 M K/Na tartrate and were vitrified 368 
using 30% ethylene glycol, 10% isopropanol. An 180o wedge of data was collected at 369 
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Diamond Light Source (I04-1) with a non-overlapping 0.5o oscillation width. Owing to 370 
systematic absences the data was indexed (Pointless) and integrated (MOSFLM) in p41212 371 
and then scaled (SCALA). Molecular replacement was performed using PHASER examining 372 
all enantiomorphs, implementing a fragment from an ankyrin repeat module with side chains 373 
removed from PDB:1N11. Upon isotropic refinement using PHENIX.refine 77 electron 374 
density for the full ankyrin repeat was visible and modelled using COOT 78. This revealed the 375 
presence of the SPN domain in the weighted difference map that was subsequently modelled 376 
at 1σ. The fully refined electron density map also revealed a significant amount of ethylene 377 
glycol and isopropyl alcohol from the cryo-protectant bound to the structure. These bound 378 
molecules were assigned and accounted for in the final refinement. Data reduction and 379 
refinement statistics are shown in Supplementary Table 1.  380 
NMR spectroscopy. NMR spectra were collected on a Bruker Avance III 600 and 800 MHz 381 
spectrometers equipped with CryoProbes. Experiments were performed at 298 K in 20 mM 382 
Tris pH 7.4, 150 mM NaCl, 2 mM DTT, with 5% (v/v) 2H2O. Spectra were processed with 383 
TopSpin (Bruker). 384 
Isothermal titration calorimetry (ITC). ITC experiments were performed using an ITC-200 385 
(Microcal). ITC titrations performed in 20 mM Tris pH 7.4, 150 mM NaCl, 0.5 mM TCEP 386 
(tris-carboxyethyl-phosphine) and 3 mM MgCl2 at 25oC. Data were integrated and fitted to a 387 
single-site binding equation using Origin 7 software with integrated ITC module (Microcal). 388 
Statistics and Reproducibility. Statistical testing was determined using the Student’s t-test 389 
(unpaired two-tailed, unequal variance) or ANOVA (followed by Dunnett’s test for multiple 390 
comparisons, where appropriate).  All experiments were repeated at least three times unless 391 
otherwise indicated. N numbers are indicated in the figure legends. P-value of 0.05 was 392 
considered as a borderline for statistical significance (P > 0.05). P-values are indicated in the 393 
figures. The experiments were not randomized. No statistical method was used to determine 394 
sample size. Investigators were not blinded to allocation during experiments and outcome 395 
assessment except for FACS assays. 396 
Data Availability. Atomic coordinates for the reported crystal structure have been deposited 397 
in the Protein Data Bank under the accession code 5G4X. Source data for figures 1e, 2a, 3b, 398 
5a, and supplementary figures S1e, S1f, S2a, S5a and S5b can be found in Supplementary 399 
Table 3. All other data supporting the findings of this study are available from the 400 
corresponding author on reasonable request. 401 
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